Sarepta therapeutics announces intent to submit an accelerated approval biologics license application for its gene therapy srp-9001 to treat duchenne muscular dystrophy

Cambridge, mass., july 29, 2022 (globe newswire) -- sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today announced its intent to submit a biologics license application (bla) seeking accelerated approval for srp-9001 (delandistrogene moxeparvovec) to treat ambulant individuals with duchenne muscular dystrophy. srp-9001 is an investigational gene therapy for duchenne being developed in partnership with roche.
SRPT Ratings Summary
SRPT Quant Ranking